KLK3 and posterior cortical atrophy: The D’Amico Risk Classification System (DRCS) is widely used to assess PCa risk of progression based on clinical parameters (initial serum prostate-specific antigen (PSA), T-stage from digital rectal examination (DRE), and biopsy Gleason Score) and is often one of the key criteria in identifying patients who might benefit from radical therapy versus active surveillance [2].